ALLMedicine™ Lipoprotein (a) Center

Apr 6th, 2021 - Suboptimal lipoprotein (a) control and residual plaque instability despite proprotein convertase subtilisin/kexin type 9 inhibitor use in heterozygous familial hypercholesterolaemia: insights from serial near-infrared spectroscopy imaging.|2021|Im...

Mar 26th, 2021 - Lipid- and lipoprotein-modifying therapies have expanded substantially in the last 25 years, resulting in reduction in the incidence of major adverse cardiovascular events. However, no specific lipoprotein (a) Lp(a)]-targeting therapy has yet been...

Mar 3rd, 2021 - Lipoprotein a (Lp (a)) and coronary artery calcification (CAC) are markers of coronary artery and cardiovascular diseases. However, the association between Lp (a) and CAC in asymptomatic individuals remains unclear. In this study, we aimed to dete...

Feb 24th, 2021 - To investigate the population attributable fraction due to elevated lipoprotein (a) (Lp(a)) and the utility of measuring Lp(a) in cardiovascular disease (CVD) risk prediction. In 413 734 participants from UK Biobank, associations of serum Lp(a) wi...

Feb 21st, 2021 - The management of heterozygous familial hypercholesterolaemia with high lipoprotein (a) and statin intolerance. The guidelines a mirage?|2021|Dal Pino B,Bigazzi F,Sbrana F,Sampietro T,|

Apr 6th, 2021 - Suboptimal lipoprotein (a) control and residual plaque instability despite proprotein convertase subtilisin/kexin type 9 inhibitor use in heterozygous familial hypercholesterolaemia: insights from serial near-infrared spectroscopy imaging.|2021|Im...

Mar 26th, 2021 - Lipid- and lipoprotein-modifying therapies have expanded substantially in the last 25 years, resulting in reduction in the incidence of major adverse cardiovascular events. However, no specific lipoprotein (a) Lp(a)]-targeting therapy has yet been...

Mar 3rd, 2021 - Lipoprotein a (Lp (a)) and coronary artery calcification (CAC) are markers of coronary artery and cardiovascular diseases. However, the association between Lp (a) and CAC in asymptomatic individuals remains unclear. In this study, we aimed to dete...

Feb 24th, 2021 - To investigate the population attributable fraction due to elevated lipoprotein (a) (Lp(a)) and the utility of measuring Lp(a) in cardiovascular disease (CVD) risk prediction. In 413 734 participants from UK Biobank, associations of serum Lp(a) wi...

Feb 21st, 2021 - The management of heterozygous familial hypercholesterolaemia with high lipoprotein (a) and statin intolerance. The guidelines a mirage?|2021|Dal Pino B,Bigazzi F,Sbrana F,Sampietro T,|

Feb 25th, 2019 - ZURICH (Reuters) - Novartis will pay $150 million to Ionis Pharmaceuticals to license an RNA-targeting cardiovascular drug as the Swiss company aims to bolster its range of heart disease treatments that now includes the blockbuster Entresto. FILE ...

May 1st, 2014 - Randomized controlled trials have unequivocally shown that lowering levels of low-density lipoprotein cholesterol (LDL-C) with statins reduces the rate of cardiovascular events. 1–3 Yet many patients still have heart attacks even though they are on.

Feb 5th, 2013 - MONTREAL, Quebec — An international consortium has identified a variation in the gene coding for lipoprotein (a) (Lp[a]), which appears to be strongly associated with aortic-valve calcification [1]. People carrying this single nucleotide polymorph...

Nov 30th, 2011 - December 1, 2011 (Houston, Texas) — Elevated levels of lipoprotein (a) [Lp(a)] are associated with cardiovascular events in African Americans, and the risk is comparable to that seen in whites, a new analysis of the Atherosclerosis Risk in Communi...

Jul 20th, 2009 - July 21, 2009 (Cambridge, United Kingdom) — A new pooled analysis of 36 prospective studies shows there is a continuous association between blood concentration of lipoprotein (a)--Lp(a)--and the risk of MI and stroke [1]. Importantly, this associa...